STAT Plus: CytoDyn’s Covid-19 drug troubles escalate: Efficacy data are missing from study
CytoDyn released safety data on its experimental drug for Covid-19 on Tuesday, but efficacy data were conspicuously absent, and the company disclosed that a patient had died following treatment with the therapy.
The cause of the patient’s death was not disclosed, but CytoDyn said the fatality occurred 33 days after enrollment in the clinical trial due to an “event unrelated” to treatment with its drug, leronlimab. No other details about the patient were provided.
